The General Court's decision in AstraZeneca has certainly been one of the most significant judgments of the Court in the field of competition law in 2010. It is the author's opinion that the Court has de facto enlarged the notion of "abuse of dominant position". From now on it includes any use of administrative procedures in such a way that can lead to the distortion of competition within the internal market.